Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
Rhea-AI Summary
IQVIA Holdings Inc. reported Q3 2023 financial results with revenue of $3,736 million, a 4.9% YoY increase. GAAP Net Income grew 7.1% YoY to $303 million. R&D Solutions quarterly bookings reached $2.6 billion with a book-to-bill ratio of 1.24x. The contracted backlog grew 12% YoY to $28.8 billion. Adjusted EBITDA increased 9.1% YoY to $888 million. The company updated its full-year guidance with a revenue growth range of 3.3% to 3.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
News
Rhea-AI Summary
Sanofi will use IQVIA's CRM platform to maximize customer interactions and innovate in the retail channel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
-
Rhea-AI Summary
CEPI and IQVIA announce strategic collaboration to advance the 100 Days Mission and strengthen global clinical research for vaccines and biological countermeasures against emerging infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
Rhea-AI Summary
IQVIA Holdings Inc. will announce its Q3 2023 financial results on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Patient organizations contribute $22.2 billion in grants over the past 5 years, according to a report by IQVIA Institute for Human Data Science.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
IQVIA announces strategic collaboration with argenx to advance treatment for rare autoimmune diseases through innovative technology-enabled pharmacovigilance (PV) safety services and solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Rhea-AI Summary
IQVIA appoints Richard Staub III as president of its Research & Development Solutions (R&DS) business unit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
-
Rhea-AI Summary
IQVIA named Leader in IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
Ron Bruehlman, CFO of IQVIA, will speak at the Baird 2023 Global Healthcare Conference on Sep 13, 2023. Webcast available on IQVIA Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
Rhea-AI Summary
IQVIA CEO to speak at Morgan Stanley Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
The current stock price of Iqvia Hldgs (IQV) is $191.04 as of February 21, 2025.
What is the market cap of Iqvia Hldgs (IQV)?
The market cap of Iqvia Hldgs (IQV) is approximately 34.2B.
What is IQVIA Holdings Inc.?
IQVIA Holdings Inc. is a global leader in integrated information and technology solutions, formed from the merger of Quintiles and IMS Health in 2016.
What services does IQVIA offer?
IQVIA offers services in research and development, technology and analytics, and contract sales for the healthcare industry.
How many employees does IQVIA have?
IQVIA has approximately 50,000 employees operating in more than 100 countries.
What is IQVIA's focus in the research and development segment?
IQVIA's R&D segment focuses on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms.
What is the role of IQVIA's technology and analytics segment?
This segment provides aggregated information and technology services, including data and analytics capabilities for clinical trials, to clients in the healthcare industry.
Does IQVIA conduct virtual clinical trials?
Yes, IQVIA conducts virtual clinical trials as part of its technology and analytics services.
What industries does IQVIA serve?
IQVIA serves pharmaceutical companies, healthcare providers, payers, and policymakers.
How does IQVIA protect patient privacy?
IQVIA is a global leader in protecting individual patient privacy while using healthcare data to deliver real-world insights.
Where can I find more information about IQVIA?
For more information, visit IQVIA's official website: www.quintilesims.com.
When was IQVIA formed?
IQVIA was formed in 2016 from the merger of Quintiles and IMS Health.
Iqvia Hldgs Inc
NYSE:IQV
IQV Rankings
IQV Stock Data
34.17B
173.17M
0.92%
94.59%
1.67%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States
DURHAM